Communiqués Alligator Bioscience AB

Actions

ATORX

SE0024173637

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
0,0209 ^SEK	-5,43%		-1,42%	-93,80%

12:06	Alligator Bioscience émet 188 millions de bons de souscription pour Fenja Capital	FW
21/09	L'augmentation de capital d'Alligator Bioscience souscrite à hauteur de 17 %	FW

Communiqués

11:46	Alligator Bioscience carries out a directed issue of warrants to Fenja Capital in connection with the completed rights issue	AQ
22/09	Alligator Bioscience announces final outcome in rights issue	AQ
21/09	Alligator Bioscience: 17% Preliminary Subscription Rate	AQ
21/09	Alligator Bioscience announces preliminary outcome in rights issue	AQ
31/08	Alligator Bioscience publishes prospectus in connection with rights issue	AQ
28/08	Alligator Bioscience (Q2 2026 Review): The HLX22 waiting game	AQ
26/08	Bulletin from the extraordinary general meeting in Alligator Bioscience AB	AQ
26/08	Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update	AQ
20/08	Alligator Bioscience : Invitation to Alligator Bioscience's earnings call on 26 August 2026	PU
20/08	Invitation to Alligator Bioscience’s earnings call on 26 August 2026	AQ
23/07	Notice of extraordinary general meeting in Alligator Bioscience AB	AQ
23/07	Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans	AQ
02/07	Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer	AQ
08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
08/05	Alligator Bioscience (Q1 2026 Review): Pragmatic Path to Phase III	AQ
06/05	Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026	AQ
05/05	Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update	AQ
28/04	Invitation to Alligator Bioscience's Earnings Call on 5 May 2026	AQ
28/04	Invitation to Alligator Bioscience’s earnings call on 5 May 2026	AQ
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
20/04	New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026	AQ
13/04	Alligator Bioscience provides an update on mitazalimab	AQ
10/04	Alligator Bioscience provides an update on mitazalimab	AQ
31/03	Change in number of shares and votes in Alligator Bioscience AB	AQ